AstraZeneca's tozorakimab posts big COPD trial gains, eyeing multi-billion-dollar sales

AstraZeneca reported positive Phase 3 results for its COPD therapy tozorakimab, showing reductions in moderate and severe flare-ups across broad patient groups, including current and former smokers and across a range of eosinophil counts, with up to 43% reductions in some subsets. The IL-33–targeting antibody is under FDA priority review with potential approval in early 2027, and AZ has lifted its peak sales forecast above $5 billion as it eyes a larger COPD biologics market beyond current options like Dupixent and Nucala.